Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor alpha-induced protein 1 (TNFAIP1) is a BTB/POZ domain-containing adapter protein that functions as a substrate-specific adapter within a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex, particularly mediating the ubiquitination and proteasomal degradation of RhoA, a small GTPase involved in cytoskeletal dynamics and cell migration[2][6]. TNFAIP1 is inducible by tumor necrosis factor alpha (TNF-α), has regulatory roles in cytoskeleton maintenance, cell migration, DNA synthesis, and DNA repair through interaction with PCNA and DNA polymerase delta. TNFAIP1 is implicated in cancer biology, being overexpressed in several cancer types and associated with adverse prognosis, notably in lung cancer. It may play roles in other conditions, such as neurodevelopmental disorders, but current data primarily support its importance in cellular homeostasis and cancer progression[1][2][6].
For drugs targeting upstream regulatory pathways (not TNFAIP1 itself): Inhibition of neddylation leads to accumulation of TNFAIP1 by preventing its degradation via the ubiquitin-proteasome system[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor alpha-induced protein 1 (TNFAIP1).